Clinical trials: Metastatic Triple-negative Breast Cancer
Metastatic Triple-negative Breast Cancer
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
This is a prospective, multicenter, randomized controlled study aimed at evaluating the efficacy and safety of Trop2-ADC monotherapy or immune combination strategy in the treatment of advanced triple-negative breast cancer.
- Trial name
- NCT06851299
- Testing
- trop2-ADC, ADC +anti-angiogenic drug, ADC + PD1 monoclonal antibody +anti-angiogenic drug
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
The study is being done to find out if the results of a pre-treatment biopsy can predict response to cisplatin and radiation treatment for patients with metastatic or recurrent triple negative breast cancer.
- Trial name
- NCT02422498
- Testing
- external beam radiation therapy, cisplatin, Biopsy of Target Tumor
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Breast Cancer, Advanced Breast Cancer
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
The multicenter, two-cohort, non-comparative, open-label, phase II clinical trial SABINA aims to analyze the safety and efficacy of MEN1611 in monotherapy and in combination with eribulin, a non-taxane chemotherapy agent, in…
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- SABINA (NCT05810870)
- Testing
- MEN1611, Eribulin
- Where
- 13 sites in Spain
- Volunteers
- 14 people
- Sponsor
- MedSIR
Triple-Negative Breast Cancer
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
- Trial name
- NCT04177108
- Testing
- Atezolizumab, Ipatasertib, Paclitaxel
- Where
- 182 sites in United States, Argentina and 35 more
- Volunteers
- 242 people
- Sponsor
- Hoffmann-La Roche
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Metastatic Ovarian Cancer, Triple Negative Breast Cancer
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
This is a Phase 1b, open-label, non-randomized, Dose Confirmation study. Subjects will be treated, once a week, with IV doses of Nerofe and low dose (20 mg/m2) Doxorubicin (6-8 hours from one another) in consecutive, 28-day…
- Trial name
- NCT03634150
- Testing
- Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.
- Where
- Israel
- Sponsor
- Immune System Key Ltd
Progression-Free-Survival, Recurrence
Clinical Study on Triple Negative Breast Cancer With Chinese Medicine
Breast cancer is one of the most serious threat to women's health of malignant tumors, also the most common causes of cancer death in women.Triple-negative breast cancer (TNBC) refers to the immunohistochemical detection of…
- Conditions
- Progression-Free-Survival, Recurrence, Overall Survival
- Trial name
- NCT03332368
- Testing
- Traditional Chinese medicine
- Where
- 5 sites in China
- Volunteers
- 620 people
- Sponsor
- Sheng Liu
TNBC
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.
- Trial name
- NCT05918133
- Testing
- PM8002, nab-paclitaxel
- Where
- 8 sites in China
- Volunteers
- 42 people
- Sponsor
- Biotheus Inc.
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma
- Trial name
- NCT04789668
- Testing
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced or Metastatic Triple-negative Breast Cancer
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
The purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously…
- Trial name
- NCT07556848
- Testing
- 9MW2821, Chemotherapy
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Triple-negative Breast Cancer
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer
To compare the therapeutic effect of vinorelbine used alone or combined with apatinib mesylate for recurrent or metastatic TNBC patients who have at least received one chemotherapy regimen, including anthracyclines and taxanes…
- Trial name
- NCT03932526
- Testing
- Vinorelbine + Apatinib
- Volunteers
- 184 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Metastatic Triple-Negative Breast Carcinoma
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
This is a prospective, multicenter, phase I/II, open-label, two-stage design of PD1+ TILs infusion in metastatic or advanced TNBC. TILS001 includes 3 parts.
- Trial name
- TILS001 (NCT05451784)
- Testing
- PD1+ TILs (NUMARZU-001) product infusion
- Where
- 4 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Fundacio Clinic Barcelona
Metastatic Triple-negative Breast Cancer
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC).
- Trial name
- NCT05746728
- Testing
- Surufatinib, Tislelizumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Huihua Xiong
Breast Cancer
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with…
- Trial name
- NCT06103864
- Testing
- Dato-DXd, Durvalumab, Paclitaxel
- Where
- 318 sites in United States, Argentina and 22 more
- Volunteers
- 625 people
- Sponsor
- AstraZeneca
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Breast Cancer
A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
The purpose of this clinical trial was to determine whether combining iniparib (BSI-201) with standard chemotherapy in estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor…
- Trial name
- NCT00540358
- Testing
- gemcitabine/carboplatin, iniparib
- Where
- 18 sites in United States
- Volunteers
- 123 people
- Sponsor
- Sanofi
Triple Negative Breast Cancer, Breast Cancer
ImmunoBreast - A Phase Ib Study
A phase Ib study to investigate the safety, tolerability and trends of efficacy of ALECSAT treatment as an add-on therapy to carboplatin and gemcitabine in patients with locally advanced or metastatic triple-negative breast…
- Conditions
- Triple Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT04609215
- Testing
- ALECSAT
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Henrik Ditzel
Triple-Negative Breast Cancer
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in…
- Trial name
- ELEVATE TNBC (NCT04958785)
- Testing
- Magrolimab, Nab-Paclitaxel, Paclitaxel
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Breast Cancer, Metastatic HER2-negative Breast
T-Cell Therapy for Advanced Breast Cancer
The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic…
- Trial name
- NCT02792114
- Testing
- Cyclophosphamide, Mesothelin-targeted T cells, AP1903
- Where
- 7 sites in United States
- Volunteers
- 186 people
- Sponsor
- Memorial Sloan Kettering Cancer Center